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Afferent signaling impairment from baroreceptors 
cannot fully explain decrease in heart rate variability 
in Marfan syndrome patients: an author’s reply
We are grateful for the interest to our paper 
reporting low heart rate variability (HRV) in Marfan 
syndrome (MS) patients with FBN1 mutations [1]. 
The author of the letter [2] raised the question 
whether low HRV is related to FBN1 mutation or 
impaired baroreflex due to aorta and large vessels 
damage in MS [3]. We fully agree with the author’s 
statement that the lesions of aorta and carotid ar­
teries like dilation, dissection, and aneurysm may 
cause impairment of afferent signaling of baroreflex 
circuits resulting in reduction of HRV. However, 
there are several reasons why we think that this is 
not the only explanation for HRV decrease in MS.
Impairment of afferent signaling from barore­
ceptors, although important, is not the only possible 
reason for suppressed heart rate oscillations [3]. 
As it was mentioned in our study, we did not ob­
serve substantial differences in HRV parameters 
of MS patients with FBN1 mutations after surgery 
compared to those who did not undergo the Bentall 
surgery. Therefore, the separate analysis of HRV 
between subgroups with and without serious aortic 
damage was not performed [1]. Besides, we did not 
observe significant signs of baroreceptor feedback 
failure such as blood pressure instability, left ven­
tricle hypertrophy, or orthostatic hypotension in 
our patients [4]. The data obtained from the HRV 
records during orthostatic testing further confirms 
the absence of clinically significant orthostatic in­
tolerance in studied patients [1]. It is known that 
the major location of baroreceptors is the carotid 
bulb. However, in MS, damage to carotid arteries 
occurs relatively less frequently compared to le­
sions in the aorta [5]. Thus, we can expect only 
a partial loss of afferent baroreceptor signaling 
in MS and it is really difficult to determine these 
changes quantitatively.
The other reasons of HRV decrease in MS pa­
tients with FBN1 mutations have been extensively 
discussed [1]. As it was hypothesized previously, 
the HRV suppression may occur in energy defi­
cient states of the cardiac pacemaker cells [6], and 
a number of conditions characterized by excessive 
inflammation, oxidative stress, insulin resistance 
and other factors. Even mild changes and early 
stages of diseases may exert suppression of HRV 
far before the first clinically significant manifes­
tation [7]. The most important possible clinical 
implications of low HRV in MS patients include 
increased risk of heart rhythm disorders and 
ventricular dysrhythmias in particular [8], which 
may be the cause of sudden death, independent of 
aortic aneurysms.
Thus, the question whether the decreased 
HRV is related to affected baroreceptor signaling or 
metabolic derangements caused by the FBN1 mu­
tation in MS patients cannot be considered solved 
and further studies providing more accurate results 
are needed. Most likely both mechanisms to some 
extent take place in these patients. Nevertheless, 
the importance of HRV determination in MS for 
evaluation of ventricular dysarrhythmias should 
not be underestimated.
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